Endo continues to see value in 505(b)(2) sterile injectables and complex generics, while “swift, tough decisions” on its more commoditised US retail generics are helping put the company ahead of its competitors.
“The short answer is yes.” Endo’s president and chief executive officer (CEO), Paul Campanelli, leaves no room for ambiguity when asked if generic injectable and 505(b)(2) hybrid injectable opportunities will continue to play a dominant role for Endo and its spending on research and development (R&D) going into 2019.
And the segment is important, a “growth driver,” in the words of Endo’s chief. In the first nine months of...
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
